Abstract
Primary CNS lymphoma is a high malignant disease of the brain which can lead rapidly to death if diagnosis and/or the start of treatment is delayed. The age at time of diagnosis is a strong factor influencing prognosis so that in younger patients <65 years of age long-term survival may be achieved in a substantial percentage of patients, while in elderly patients long-term survival is seen much more rarely. First-line therapy consists of high-dose methotrexate-based (poly)chemotherapy. This review provides an overview of clinical presentation, steps to diagnosis, detailed information about current treatment concepts and specific information for particular clinical situations.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Central Nervous System Neoplasms / diagnosis
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / pathology
-
Central Nervous System Neoplasms / radiotherapy
-
Chemoradiotherapy / adverse effects
-
Diagnosis, Differential
-
Evidence-Based Medicine*
-
Humans
-
Lymphoma / diagnosis
-
Lymphoma / drug therapy*
-
Lymphoma / pathology
-
Lymphoma / radiotherapy
-
Lymphoma, Large B-Cell, Diffuse / diagnosis
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Lymphoma, Large B-Cell, Diffuse / radiotherapy
-
Lymphoma, Non-Hodgkin / diagnosis
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / pathology
-
Lymphoma, Non-Hodgkin / radiotherapy
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Prognosis
Substances
-
Antimetabolites, Antineoplastic
-
Methotrexate